Core Viewpoint - Qingdao Haitai Newlight Technology Co., Ltd. plans to temporarily use idle raised funds not exceeding RMB 150 million to supplement working capital, which will be used solely for business expansion and daily operations related to its main business [2][7][8]. Group 1: Announcement of Fund Usage - The company held its fourth board meeting and supervisory board meeting on August 1, 2025, where it approved the proposal to use idle raised funds for working capital [2][8]. - The usage period for the funds is valid for 12 months from the date of board approval, and the amount can be rolled over within this period [2][7]. Group 2: Fundraising Background - The company successfully raised a total of RMB 778.85 million through the issuance of 21,780,000 shares at a price of RMB 35.76 per share, with a net amount of RMB 693.52 million after deducting underwriting fees and other expenses [3][4]. - The raised funds were deposited into a special account for management and usage, with agreements signed with relevant parties to ensure proper oversight [4]. Group 3: Fund Investment Projects - The company has completed several fundraising projects, including the construction of an endoscope system production base and a research and experimental center, which were concluded by December 2023 [5][6]. - The company has also approved extensions and adjustments to the timelines and implementation entities for certain fundraising projects [6]. Group 4: Supervisory Board Opinions - The supervisory board agrees that the proposed use of idle funds does not change the intended use of the raised funds and will not affect the normal progress of investment projects [9][14]. - The board confirmed that the funds will only be used for daily operations related to the main business and will not harm the interests of the company and its shareholders [9][14].

Core Viewpoint - Qingdao Haitai Newlight Technology Co., Ltd. plans to temporarily use idle raised funds not exceeding RMB 150 million to supplement working capital, which will be utilized for business expansion and daily operations related to its main business activities [1][6][7]. Group 1: Fundraising Overview - The company was approved to publicly issue 21,780,000 shares at a price of RMB 35.76 per share, raising a total of RMB 778.85 million, with a net amount of RMB 693.52 million after deducting underwriting fees [2]. - The raised funds were deposited into a special account established for managing the raised funds, and the company has signed tripartite and quadripartite supervision agreements with relevant parties [3]. Group 2: Fund Usage Plan - The company has outlined its fundraising investment projects, including the construction of an endoscope system production base and a research and experimental center, with a total planned investment of RMB 86.24 million [3]. - The company has completed the aforementioned projects by December 2023, as disclosed in a previous announcement [3]. Group 3: Approval Process - The board of directors and the supervisory board approved the proposal to use idle funds on August 1, 2025, and this proposal does not require submission to the shareholders' meeting [1][6]. - The proposal has been reviewed and agreed upon by the sponsor, Guotai Junan Securities Co., Ltd., confirming compliance with relevant regulations [7][8]. Group 4: Monitoring and Compliance - The supervisory board has expressed that the use of idle funds will not change the intended use of the raised funds and will not affect the normal progress of the investment projects [7]. - The sponsor has verified that the use of funds complies with the regulatory requirements and the company's fundraising management system [8].